NT-I7 for Kaposi Sarcoma in Patients With or Without HIV

Phase 1 Terminated 8 enrolled Fred Hutchinson Cancer Center Cancer Immunotherapy Trials Network (CITN) · collab National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

This phase I trial studies the best dose and effects of NT-I7 in treating Kaposi sarcoma in patients with or without HIV. NT-I7 works by using a patient's immune system to fight cancer. It is made in a laboratory and is used to boost, direct, or restore the body's natural defenses against cancer. NT-I7 may work better in treating Kaposi sarcoma.

Timeline

Start: 2022-05-23
Primary completion: 2023-12-15
Completion: 2023-12-15

Publications

Ramaswami R, Kask AS, D'Amico L, Menon MP, Lurain K, Yarchoan R, Ekwede I, Couey P, Burnham E, Angeldekao A, Ha Lee B, Kaiser JC, Cheever M, Uldrick TS, Kwok LL, Wright A, Fling SP, Wang CJ. Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma. J Immunother Cancer. 2025 Feb 6;13(2):e010291. doi: 10.1136/jitc-2024-010291.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NT-I7	Protein / enzyme biologic	480 ug/kg	Intramuscular
Subject	NT-I7	Protein / enzyme biologic	960 ug/kg	Intramuscular
Subject	NT-I7	Protein / enzyme biologic	1200 ug/kg	Intramuscular

NT-I7 for Kaposi Sarcoma in Patients With or Without HIV

Summary

Timeline

Publications

Drugs

Indications